Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk

Andrea Tampieri, Valentina Cipriano, Fabrizio Mucci, Anna Maria Rusconi, Tiziano Lenzi, Patrizia Cenni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Currently, there is no unified consensus on short-term anticoagulation after cardioversion of atrial fibrillation lasting less than 48 h in low-cardioembolic-risk patients. The aim of this study is to evaluate the rate of transient ischemic attacks, stroke and death in this subset of patients after cardioversion without post-procedural anticoagulation. In a prospective observational study, patients with recent-onset AF undergoing cardioversion attempts in the Emergency Department were evaluated over the past 3 years. Inclusion criteria were conversion to sinus rhythm, low thromboembolic risk defined by a CHA2DS2VASc score of 0–1 points for males (0–2 points for females aged over 65 years), and hospital discharge without anticoagulant treatment. Patients with severe valvular heart disease, underlying systemic causes of AF, and those discharged with anticoagulant therapy were excluded. The main outcomes measured were TIA, stroke and death at thirty days' follow-up after discharge. During the study period, 218 successful cardioversions, obtained both electrically and pharmacologically, were performed on 157 patients. One hundred and eleven patients were males (71%), the mean age was 55.2 years (±standard deviation 10.7), 99 patients (63%) reported a CHA2DS2VASc score of 0, and the remaining 58 (37%) had a risk profile of 1 point. Of these, latter 8 were females (5%) older than 65 years (risk score 2 points). At the thirty days outcome, none of the 150 enrolled patients who completed a follow-up visit has reported TIA or stroke, nor died, in the overall 211 successful cardioversions evaluated. In our study, the rate of thromboembolic events after cardioversion of recent-onset AF of less than 48 h duration, in patients with a 0–1 CHA2DS2VASc risk profile (females 0–2), appeared to be extremely low even in absence of post-procedural anticoagulation. These findings seem to confirm data from previous studies, and suggest that routine post-procedural short-term anticoagulation may be considered as an overtreatment in this very low-risk subset of patients.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalInternal and Emergency Medicine
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Electric Countershock
Atrial Fibrillation
Safety
Stroke
Anticoagulants
Heart Valve Diseases
Transient Ischemic Attack
Observational Studies
Hospital Emergency Service
Prospective Studies

Keywords

  • Atrial fibrillation
  • Cardioembolic risk
  • Cardioversion
  • Short-term anticoagulation
  • Stroke

ASJC Scopus subject areas

  • Internal Medicine
  • Emergency Medicine

Cite this

Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk. / Tampieri, Andrea; Cipriano, Valentina; Mucci, Fabrizio; Rusconi, Anna Maria; Lenzi, Tiziano; Cenni, Patrizia.

In: Internal and Emergency Medicine, Vol. 13, No. 1, 01.01.2018, p. 87-93.

Research output: Contribution to journalArticle

Tampieri, Andrea ; Cipriano, Valentina ; Mucci, Fabrizio ; Rusconi, Anna Maria ; Lenzi, Tiziano ; Cenni, Patrizia. / Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk. In: Internal and Emergency Medicine. 2018 ; Vol. 13, No. 1. pp. 87-93.
@article{bc36f95705a2481594a4d47c456b2566,
title = "Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk",
abstract = "Currently, there is no unified consensus on short-term anticoagulation after cardioversion of atrial fibrillation lasting less than 48 h in low-cardioembolic-risk patients. The aim of this study is to evaluate the rate of transient ischemic attacks, stroke and death in this subset of patients after cardioversion without post-procedural anticoagulation. In a prospective observational study, patients with recent-onset AF undergoing cardioversion attempts in the Emergency Department were evaluated over the past 3 years. Inclusion criteria were conversion to sinus rhythm, low thromboembolic risk defined by a CHA2DS2VASc score of 0–1 points for males (0–2 points for females aged over 65 years), and hospital discharge without anticoagulant treatment. Patients with severe valvular heart disease, underlying systemic causes of AF, and those discharged with anticoagulant therapy were excluded. The main outcomes measured were TIA, stroke and death at thirty days' follow-up after discharge. During the study period, 218 successful cardioversions, obtained both electrically and pharmacologically, were performed on 157 patients. One hundred and eleven patients were males (71{\%}), the mean age was 55.2 years (±standard deviation 10.7), 99 patients (63{\%}) reported a CHA2DS2VASc score of 0, and the remaining 58 (37{\%}) had a risk profile of 1 point. Of these, latter 8 were females (5{\%}) older than 65 years (risk score 2 points). At the thirty days outcome, none of the 150 enrolled patients who completed a follow-up visit has reported TIA or stroke, nor died, in the overall 211 successful cardioversions evaluated. In our study, the rate of thromboembolic events after cardioversion of recent-onset AF of less than 48 h duration, in patients with a 0–1 CHA2DS2VASc risk profile (females 0–2), appeared to be extremely low even in absence of post-procedural anticoagulation. These findings seem to confirm data from previous studies, and suggest that routine post-procedural short-term anticoagulation may be considered as an overtreatment in this very low-risk subset of patients.",
keywords = "Atrial fibrillation, Cardioembolic risk, Cardioversion, Short-term anticoagulation, Stroke",
author = "Andrea Tampieri and Valentina Cipriano and Fabrizio Mucci and Rusconi, {Anna Maria} and Tiziano Lenzi and Patrizia Cenni",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11739-016-1589-1",
language = "English",
volume = "13",
pages = "87--93",
journal = "Internal and Emergency Medicine",
issn = "1828-0447",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk

AU - Tampieri, Andrea

AU - Cipriano, Valentina

AU - Mucci, Fabrizio

AU - Rusconi, Anna Maria

AU - Lenzi, Tiziano

AU - Cenni, Patrizia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Currently, there is no unified consensus on short-term anticoagulation after cardioversion of atrial fibrillation lasting less than 48 h in low-cardioembolic-risk patients. The aim of this study is to evaluate the rate of transient ischemic attacks, stroke and death in this subset of patients after cardioversion without post-procedural anticoagulation. In a prospective observational study, patients with recent-onset AF undergoing cardioversion attempts in the Emergency Department were evaluated over the past 3 years. Inclusion criteria were conversion to sinus rhythm, low thromboembolic risk defined by a CHA2DS2VASc score of 0–1 points for males (0–2 points for females aged over 65 years), and hospital discharge without anticoagulant treatment. Patients with severe valvular heart disease, underlying systemic causes of AF, and those discharged with anticoagulant therapy were excluded. The main outcomes measured were TIA, stroke and death at thirty days' follow-up after discharge. During the study period, 218 successful cardioversions, obtained both electrically and pharmacologically, were performed on 157 patients. One hundred and eleven patients were males (71%), the mean age was 55.2 years (±standard deviation 10.7), 99 patients (63%) reported a CHA2DS2VASc score of 0, and the remaining 58 (37%) had a risk profile of 1 point. Of these, latter 8 were females (5%) older than 65 years (risk score 2 points). At the thirty days outcome, none of the 150 enrolled patients who completed a follow-up visit has reported TIA or stroke, nor died, in the overall 211 successful cardioversions evaluated. In our study, the rate of thromboembolic events after cardioversion of recent-onset AF of less than 48 h duration, in patients with a 0–1 CHA2DS2VASc risk profile (females 0–2), appeared to be extremely low even in absence of post-procedural anticoagulation. These findings seem to confirm data from previous studies, and suggest that routine post-procedural short-term anticoagulation may be considered as an overtreatment in this very low-risk subset of patients.

AB - Currently, there is no unified consensus on short-term anticoagulation after cardioversion of atrial fibrillation lasting less than 48 h in low-cardioembolic-risk patients. The aim of this study is to evaluate the rate of transient ischemic attacks, stroke and death in this subset of patients after cardioversion without post-procedural anticoagulation. In a prospective observational study, patients with recent-onset AF undergoing cardioversion attempts in the Emergency Department were evaluated over the past 3 years. Inclusion criteria were conversion to sinus rhythm, low thromboembolic risk defined by a CHA2DS2VASc score of 0–1 points for males (0–2 points for females aged over 65 years), and hospital discharge without anticoagulant treatment. Patients with severe valvular heart disease, underlying systemic causes of AF, and those discharged with anticoagulant therapy were excluded. The main outcomes measured were TIA, stroke and death at thirty days' follow-up after discharge. During the study period, 218 successful cardioversions, obtained both electrically and pharmacologically, were performed on 157 patients. One hundred and eleven patients were males (71%), the mean age was 55.2 years (±standard deviation 10.7), 99 patients (63%) reported a CHA2DS2VASc score of 0, and the remaining 58 (37%) had a risk profile of 1 point. Of these, latter 8 were females (5%) older than 65 years (risk score 2 points). At the thirty days outcome, none of the 150 enrolled patients who completed a follow-up visit has reported TIA or stroke, nor died, in the overall 211 successful cardioversions evaluated. In our study, the rate of thromboembolic events after cardioversion of recent-onset AF of less than 48 h duration, in patients with a 0–1 CHA2DS2VASc risk profile (females 0–2), appeared to be extremely low even in absence of post-procedural anticoagulation. These findings seem to confirm data from previous studies, and suggest that routine post-procedural short-term anticoagulation may be considered as an overtreatment in this very low-risk subset of patients.

KW - Atrial fibrillation

KW - Cardioembolic risk

KW - Cardioversion

KW - Short-term anticoagulation

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85007158136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007158136&partnerID=8YFLogxK

U2 - 10.1007/s11739-016-1589-1

DO - 10.1007/s11739-016-1589-1

M3 - Article

AN - SCOPUS:85007158136

VL - 13

SP - 87

EP - 93

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

SN - 1828-0447

IS - 1

ER -